ArticleFrontiers in immunology2025
An integrated mutation-based immunoinformatic approach incorporating variability in epitopes: a study based on HIV subtype C.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus.Scientific reports · 2026Article
- Epitope-based vaccine of NiV targeting glycoprotein and fusion protein: an integrated immunoinformatics and bioinformatics approach.Virus research · 2026Article
- Designing of a conserved subunit multiepitope vaccine candidate against Francisella tularensis Schu S4 using immunoinformatics.Scientific reports · 2026Article
- Designing potent and immunogenic epitope based peptide vaccine against all serotypes of DENV via structural, physico-chemical and immunoinformatics-based approaches.Scientific reports · 2026Article
- Immunoinformatics-based design of artificial chimeric proteins as universal vaccine candidates against foot-and-mouth disease virus serotypes A, O, and SAT2.Scientific reports · 2026Article
- Integrative immunoinformatics and molecular modeling approaches for the rational design and in silico validation of a multi-epitope vaccine candidate against human herpesvirus 7.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- In silico design and immunogenicity evaluation of a multi-epitope vaccine against EV-A71.Journal of computer-aided molecular design · 2026Article
- Design of a novel proteome-derived scaffold presenting epitopes of Pseudomonas aeruginosa in native conformation.Scientific reports · 2026Article
- Integrative bioinformatics approach to the mRNA vaccine development for the human papillomavirus using the capsid protein.Biology direct · 2026Article
- Retinoids enhance NK effector function against HIV-infected CD4 T cells.Journal of virology · 2026Article
- Design and computational evaluation of a prophylactic and therapeutic multi-epitope vaccine candidate against cervical cancer.Virology journal · 2026Article
- In silico design and immunoinformatics assessment of a multiepitope vaccine targeting borealpox virus.Scientific reports · 2026Article
- Immunoinformatics-based design and evaluation of a multi-epitope vaccine against Vibrio fluvialis.Scientific reports · 2026Article
- Multi-epitope vaccine design against human metapneumovirus via reverse vaccinology and molecular modelling.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, HIV (human immunodeficiency virus) infection is one of the leading complications in public health and causes acquired immunodeficiency syndrome (AIDS), especially in the African region. No specific vaccine is available to combat this, with multi-strain variability being one of the hurdles. In this investigation, we employed variability in the epitope of the HIV subtype C targets to introduce mutations and construct an epitope-based vaccine. Four targets were examined to predict the B and T cells (major histocompatibility complex class I and II). Among the predicted epitopes, immunodominant epitopes were selected and were mapped with the identified variable amino acid to incorporate mutation. These selected and mutated epitopes were used for the non-mutated and mutated vaccine construction, considering linker for fusion and adjuvant to improve the activity. The vaccine's structure was modeled and examined to validate its structural quality, and a high population coverage was also found. The docking investigation of the non-mutated and mutated vaccine with Toll-like receptor 3 shows remarkable activity followed by strong binding affinity, and the simulation of over 100 ns revealed the constancy of the complex system. The immune response revealed its strong effectiveness by generating multiple immunoglobulins followed by the time step of infection, and further,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.